Latest News - Omeros

Wednesday, June 14, 2017 | Clinical Trials, Omeros

FDA Grants Breakthrough Therapy Designation to Omeros’ MASP-2 Inhibitor OMS721 for the Treatment of IgA Nephropathy

Omeros announced that the FDA has granted breakthrough therapy designation to OMS721 for the treatment of Immunoglobulin A (IgA) nephropathy. OMS721 is Omeros’ lead human monoclonal antibody tar…

Read the full story

Monday, November 21, 2016 | Clinical Trials, Omeros

Omeros Announces Successful Outcome of Omidria Pediatric Cataract Trial

Omeros announced the successful outcome of its recently completed post-marketing clinical trial of the effect of Omidria (phenylephrine and ketorolac injection) 1%/0.3% in pediatric patients undergoin…

Read the full story

Thursday, May 19, 2016 | Earnings & Financials, Omeros

Omeros Announces Debt Financing Transaction for $20 Million in Additional Funds

Omeros announced that it has entered into an amendment to its existing credit facility with Oxford Finance LLC and East West Bank to provide the company with an additional $20 million in unrestricted …

Read the full story

Wednesday, April 27, 2016 | Conferences, Omeros

Omeros Announces Independent Studies with Omidria to Be Presented at Upcoming Ophthalmology Congresses

Omeros announced that new research related to the clinical utility of Omidria (phenylephrine and ketorolac injection) 1% / 0.3% and the importance of preempting intraoperative miosis and inflammation …

Read the full story

Monday, January 18, 2016 | Clinical Trials, Omeros

Disclosure of Omidria Post-Launch Study Findings to Occur at Hawaiian Eye and Retina Conference

Omeros announced that Omidria (phenylephrine and ketorolac injection) 1% / 0.3% will be the focus of a series of presentations and panel discussions by thought leaders in cataract surgery at Hawaiian …

Read the full story

Thursday, October 15, 2015 | Product Releases, Omeros

Omeros Announces OMIDRIAssure to Expand Patient Access to Omidria

Omeros announced that it has launched OMIDRIAssure, a reimbursement services program to provide expanded access to Omidria (phenylephrine and ketorolac injection) 1%/0.3% for cataract surgery patients…

Read the full story

Monday, August 17, 2015 | Corporate Lawsuits, Omeros

Omeros Announces Plan to File Infringement Suit Against ANDA Filer

Omeros today, in response to investor questions, announced that it plans to file a patent infringement lawsuit against Par Pharmaceutical and its subsidiary, Par Sterile Products, LLC, in response to …

Read the full story

Tuesday, May 26, 2015 | Cataract Surgery, Omeros

Omidria Receives Positive Opinion from European Regulators

Omeros announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Omidria (phenylephrine and ketorolac injection 1%/0.3…

Read the full story

Friday, April 03, 2015 | Product Releases, Omeros

Omeros Announces the US Commercial Launch of Omidria

Omeros announced the nationwide commercial availability of Omidria (phenylephrine and ketorolac injection) 1%/0.3%, according to a company news release. Omidria is the first and only product app…

Read the full story